16.60
Pharvaris Nv stock is traded at $16.60, with a volume of 189.85K.
It is down -0.72% in the last 24 hours and down -3.88% over the past month.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
See More
Previous Close:
$16.72
Open:
$16.97
24h Volume:
189.85K
Relative Volume:
2.89
Market Cap:
$904.53M
Revenue:
-
Net Income/Loss:
$-143.59M
P/E Ratio:
-5.879
EPS:
-2.8236
Net Cash Flow:
$-119.47M
1W Performance:
+3.81%
1M Performance:
-3.88%
6M Performance:
-24.20%
1Y Performance:
-12.17%
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
PHVS
Pharvaris Nv
|
16.60 | 871.35M | 0 | -143.59M | -119.47M | -2.8236 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
Sep-25-23 | Initiated | Wedbush | Outperform |
Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Oct-05-22 | Initiated | Bryan Garnier | Buy |
Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
May-25-22 | Initiated | JMP Securities | Mkt Outperform |
Mar-02-21 | Initiated | BofA Securities | Neutral |
Mar-02-21 | Initiated | Morgan Stanley | Overweight |
Mar-02-21 | Initiated | Oppenheimer | Outperform |
Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
Pharvaris (NASDAQ:PHVS) Shares Acquired by Deutsche Bank AG - Defense World
Northern Trust Corp Purchases 76,188 Shares of Pharvaris (NASDAQ:PHVS) - Defense World
How To Trade (PHVS) - news.stocktradersdaily.com
Cubist Systematic Strategies LLC Purchases New Holdings in Pharvaris (NASDAQ:PHVS) - Defense World
New Clinical Data Reveals Long-Term Success of Oral HAE Treatment Deucrictibant - Stock Titan
Pharvaris (NASDAQ:PHVS) Shares Gap Down – Here’s What Happened - Defense World
Brokers Offer Predictions for Pharvaris FY2025 Earnings - Defense World
Q2 Earnings Forecast for Pharvaris Issued By Leerink Partnrs - Defense World
Cantor Fitzgerald Cuts Pharvaris (NASDAQ:PHVS) Price Target to $25.00 - Defense World
Research Analysts Issue Forecasts for Pharvaris Q2 Earnings - Defense World
Pharvaris (NASDAQ:PHVS) Holdings Decreased by Barclays PLC - Defense World
The Manufacturers Life Insurance Company Reduces Stake in Pharvaris (NASDAQ:PHVS) - Defense World
Pharvaris (NASDAQ:PHVS) Shares Down 5.1% on Disappointing Earnings - Defense World
Transcript : Pharvaris N.V. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08 - marketscreener.com
PHVS Reports Decrease in Cash Reserves by March Quarter End | PH - GuruFocus
Pharvaris (PHVS) Target Price Revised by Cantor Fitzgerald | PHV - GuruFocus
Pharvaris (PHVS) Target Price Increased by Wedbush Amid Clinical Progress | PHVS Stock News - GuruFocus
Wedbush Adjusts Pharvaris Price Target to $17 From $25, Maintains Outperform Rating - marketscreener.com
(PHVS) Long Term Investment Analysis - news.stocktradersdaily.com
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update - marketscreener.com
Pharvaris Hits Major FDA Milestone for HAE Drug Pipeline While Phase 3 Trials Show Strong Progress - Stock Titan
Pharvaris (PHVS) Expected to Announce Earnings on Wednesday - Defense World
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4 - Stock Titan
Pharvaris (NASDAQ:PHVS) Shares Acquired by JPMorgan Chase & Co. - Defense World
When (PHVS) Moves Investors should Listen - news.stocktradersdaily.com
Pharvaris NV expected to post a loss of 76 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $735,000 Stock Position in Pharvaris (NASDAQ:PHVS) - Defense World
Pharvaris (NASDAQ:PHVS) Holdings Increased by Legal & General Group Plc - Defense World
Pharvaris (NASDAQ:PHVS) Research Coverage Started at Cantor Fitzgerald - Defense World
Analysts Offer Predictions for Pharvaris FY2025 Earnings - Defense World
Cantor Fitzgerald Initiates Pharvaris at Overweight With $28 Price Target - marketscreener.com
JMP reiterates Pharvaris stock with $55 target, positive outlook By Investing.com - Investing.com UK
Where are the Opportunities in (PHVS) - news.stocktradersdaily.com
What is Leerink Partnrs’ Forecast for Pharvaris Q1 Earnings? - The AM Reporter
5,800 Shares in Pharvaris (NASDAQ:PHVS) Acquired by KLP Kapitalforvaltning AS - Defense World
What is Leerink Partnrs’ Estimate for Pharvaris Q1 Earnings? - Defense World
Wedbush Issues Pessimistic Forecast for Pharvaris Earnings - Defense World
What is Wedbush’s Forecast for Pharvaris FY2029 Earnings? - Defense World
Pharvaris NV reports results for the quarter ended December 31Earnings Summary - TradingView
Pharvaris Reports 2024 Financial Results and Business Progress - TipRanks
Pharvaris Accelerates HAE Drug Development: Phase 3 Trial Fully Enrolled, €281M War Chest - Stock Titan
Pharvaris (PHVS) Projected to Post Earnings on Wednesday - Defense World
(PHVS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Pharvaris Says EU Orphan Designation Received for Deucrictibant - MarketScreener
Major EU Breakthrough: Pharvaris' Angioedema Drug Gains Coveted Orphan Status - Stock Titan
(PHVS) Technical Data - news.stocktradersdaily.com
Can Pharvaris Impress Investors at Upcoming Leerink Conference? - StockTitan
How to Take Advantage of moves in (PHVS) - Stock Traders Daily
We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth - Yahoo Finance
(PHVS) Trading Report - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Sees Significant Increase in Short Interest - MarketBeat
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):